Bone Marrow Mesenchymal Stem Cells for Heart Failure Treatment: A Systematic Review and Meta-Analysis - 01/08/23
, Abdullah Murhaf Al-Khani, MBBS 1 , Khawaja Husnain Haider, PhD ⁎ Abstract |
Aim |
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are the most well-studied and characterised stem cell types. This review was undertaken of the current available phase II/III randomised clinical trials (RCTs) that delivered BM-MSCs to treat patients with cardiomyopathy, and to assess their performance.
Methods |
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed during the systematic review and meta-analysis. Eligible studies were reviewed, and their data charted. To assess the efficacy of BM-MSCs, the outcome was improvement in left ventricular ejection fraction (LVEF) and 6-minute walking distance (6MWD).
Results |
The pooled weighted mean difference (WMD) showed that BM-MSCs treatment improved the 6MWD by 27.86 m (95% CI 0.11–55.6 m) compared with the control groups. The pooled WMD showed that BM-MSCs treatment improved the LVEF by 6.37% (95% CI 5.48%–7.26%) compared with the control groups.
Conclusion |
BM-MSCs treatment is an effective intervention for managing patients with heart failure, but it requires larger and more robust clinical trials to support its routine use in clinics.
Le texte complet de cet article est disponible en PDF.Keywords : Bone marrow mesenchymal cell, Clinical trial, Heart failure, Meta-analysis, Stem cell, Systematic review
Plan
Vol 32 - N° 7
P. 870-880 - juillet 2023 Retour au numéro
Article précédent
- New Drug Targets and Preclinical Modelling Recommendations for Treating Acute Myocardial Infarction
- Yuanzhao Cao, Meredith A. Redd, Chen Fang, Dalia Mizikovsky, Xichun Li, Peter S. Macdonald, Glenn F. King, Nathan J. Palpant
- National Hypertension Taskforce
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?